Appili Therapeutics Inc has seen significant volatility recently, with a notable drop in its stock price.
This week, Appili Therapeutics Inc (APLI.TO) experienced a sharp decline in its stock price, closing at C$0.01, a decrease of 33.33% over the past week. With no major company news driving this price action, investors are left to analyze the technical indicators and historical performance of the stock.
Investor takeaway: Investors should closely monitor Appili's technical indicators and market developments, especially in light of its ongoing projects and the recent termination of its contract with NIAID.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
-33.33%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
238.3%
Annualized
90-Day Vol
232.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.03 |
| 90 trading days | C$0.01 | C$0.00 – C$0.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Analysts have set an average target of C$0.15 for Appili, indicating a significant potential upside if the company can effectively navigate its current challenges.
Bear case
Appili faces considerable financial hurdles, with a market cap of just over C$1.3 million and a troubling negative return on equity. These factors could undermine investor confidence.
Recent Price Action
Appili Therapeutics Inc (APLI.TO) closed at C$0.01 this week, reflecting a 33.33% decline over the past week and a staggering 60% drop year-to-date. The stock has been under pressure, with a significant increase in trading volume, reaching 300,080 shares compared to the 20-day average of 58,841 shares, indicating heightened investor activity.
Company News and Developments
Despite the substantial drop in stock price, there has been no major news from Appili Therapeutics this week. However, previous headlines indicate ongoing challenges, including the recent termination of their contract with the National Institute of Allergy and Infectious Diseases (NIAID) regarding the VXV-01 program. This contract termination could have contributed to investor uncertainty and the stock's decline.
Advertisement
Technical Picture
From a technical standpoint, Appili's stock is currently trading at the lower end of its 52-week range of C$0.01 to C$0.04. The stock is significantly below both its 50-day moving average of C$0.01 and its 200-day moving average of C$0.02, indicating a bearish trend. The beta of -0.20 suggests that the stock has historically been less volatile than the broader market, though recent price action contradicts this trend.
Insider Activity
No insider activity has been reported for Appili Therapeutics in recent weeks, which may indicate a lack of confidence among insiders regarding the company’s immediate prospects.
Price Action Summary
As of the last close, Appili Therapeutics Inc (APLI.TO) remains at C$0.01, showcasing a 1D change of 0.00%. Investors will need to keep a close eye on future developments and market reactions as the company navigates its operational challenges.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
